Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary

2013 ◽  
Vol 18 (21-22) ◽  
pp. 1052-1066 ◽  
Author(s):  
Monika A. Jarzabek ◽  
Kieron J. Sweeney ◽  
Rhys L. Evans ◽  
Andreas H. Jacobs ◽  
Roger Stupp ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Novel Treatment ◽  
Treatment Paradigm

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

2020 ◽  
Vol 82 (5) ◽  
pp. 1094-1101 ◽  
Author(s):  
Mondana H. Ghias ◽  
Andrew D. Johnston ◽  
Allison J. Kutner ◽  
Robert G. Micheletti ◽  
H. Dean Hosgood ◽  
...  
Keyword(s):  
High Frequency ◽  
Hidradenitis Suppurativa ◽  
High Dose ◽  
Novel Treatment ◽  
Treatment Paradigm

scholarly journals Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

2021 ◽  
Author(s):  
Anna Zakrzewicz ◽  
Celina Würth ◽  
Benedikt Beckert ◽  
Simon Feldhoff ◽  
Katrien Vanderheyden ◽  
...  
Keyword(s):  
Pemphigus Vulgaris ◽  
Human Keratinocytes ◽  
Epidermal Keratinocytes ◽  
Target Cells ◽  
Direct Role ◽  
Autoimmune Blistering Disease ◽  
Novel Treatment ◽  
Igg Binding ◽  
Treatment Paradigm ◽  
Desmoglein 3

Pemphigus vulgaris is an autoimmune blistering disease of the epidermis, caused by autoantibodies against desmosomal proteins, mainly desmogleins 1 and 3, which induce an impairment of desmosomal adhesion and blister formation. Recent findings have shown that inhibition of immunoglobulin G binding on the neonatal Fc receptor, FcRn, results in reduced autoantibody recycling and shortens their half-life, providing a valid treatment option for PV. We have here analyzed the role of FcRn in human keratinocytes treated with novel, recombinant anti-desmoglein-3 antibodies that induce pathogenic changes in desmosomes, such as loss of monolayer integrity, aberrant desmoglein-3 localization and degradation of desmoglein-3. We show that blocking IgG binding on FcRn by efgartigimod, a recombinant Fc fragment that is undergoing clinical studies for pemphigus, stabilizes the keratinocyte monolayer, whereas the loss of desmoglein-3 is not prevented by efgartigimod. Our data show for the first time that FcRn may play a direct role in the pathogenesis of pemphigus at the level of the autoantibody target cells, the epidermal keratinocytes. Our data also imply that in keratinocytes, FcRn may have functions different from its known function in IgG recycling. Therefore, stabilization of keratinocyte adhesion by FcRn blocking entities may provide a novel treatment paradigm for pemphigus.

scholarly journals Proposed novel treatment paradigm of aberrant gait and balance kinematics in patients with severe COPD

Respirology ◽  
2021 ◽  
Author(s):  
Malvika Kaul ◽  
Sai Sunkara ◽  
Matthew J. Major ◽  
Keith E. Gordon ◽  
Israel Rubinstein
Keyword(s):  
Novel Treatment ◽  
Treatment Paradigm ◽  
Severe Copd

A case report of informal cognitive therapy of delusions by a carer: a novel treatment paradigm?

2005 ◽  
Vol 20 (1) ◽  
pp. 80-81 ◽  
Author(s):  
Sanju George ◽  
Sumithra Bandopadhay ◽  
Colin Cowan
Keyword(s):  
Case Report ◽  
Cognitive Therapy ◽  
Psychotic Symptoms ◽  
Cognitive Treatment ◽  
Novel Treatment ◽  
Treatment Paradigm ◽  
Future Work

AbstractCognitive therapy has been effectively used in the treatment of psychotic symptoms like delusions and hallucinations. Most of the work in this area has focused only on the patient. We describe a patient with schizophrenia, whose delusions were well managed by his mother using informal cognitive therapy principles. Primary carers could be more involved as ‘co-therapists’ in the cognitive treatment of psychotic symptoms in some patients. Future work needs to explore the effectiveness and feasibility of more structured cognitive therapy input for carers (as co-therapists) of patients with psychosis.

Abstract 5090: Targeted inhibition of MEK and AKT pathways in combination with radiation as a novel treatment paradigm in pancreatic cancer

2011 ◽  
Author(s):  
Terence M. Williams ◽  
Athena Flecha ◽  
Ashwin N. Ram ◽  
Paul R. Keller ◽  
Stefanie Galban ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Novel Treatment ◽  
Treatment Paradigm ◽  
Targeted Inhibition
Sign in / Sign up

Export Citation Format

Share Document